[New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer]

Matthieu Roulleaux Dugage; Friederike Schlürmann

doi:10.1016/j.bulcan.2023.03.012

[New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer]

Bull Cancer. 2023 Jun;110(6):600-602. doi: 10.1016/j.bulcan.2023.03.012. Epub 2023 Apr 12.

[Article in French]

Authors

Matthieu Roulleaux Dugage¹, Friederike Schlürmann²

Affiliations

¹ AP-HP, hôpital européen Georges-Pompidou, oncologie médicale, Paris, France. Electronic address: [email protected].
² Institut de cancérologie de Cornouaille, CHIC Quimper, Quimper, France; CHU de Brest, Institut de cancérologie et hématologie, Brest, France.

PMID: 37059642
DOI: 10.1016/j.bulcan.2023.03.012

No abstract available

Keywords: Cancer de prostate métastatique résistant à la castration; Lutetium; Metastatic castration-resistant prostate cancer; PSMA-PET; TEP-PSMA; Vipivotide tetraxetan.

Publication types

Letter

MeSH terms

Humans
Lutetium* / therapeutic use
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology
Radiopharmaceuticals
Treatment Outcome

Substances

Lutetium
Radiopharmaceuticals
Prostate-Specific Antigen